Author:
Greenhalf William,Ghaneh Paula,Neoptolemos John P.,Palmer Daniel H.,Cox Trevor F.,Lamb Richard F.,Garner Elizabeth,Campbell Fiona,Mackey John R.,Costello Eithne,Moore Malcolm J.,Valle Juan W.,McDonald Alexander C.,Carter Ross,Tebbutt Niall C.,Goldstein David,Shannon Jennifer,Dervenis Christos,Glimelius Bengt,Deakin Mark,Charnley Richard M.,Lacaine François,Scarfe Andrew G.,Middleton Mark R.,Anthoney Alan,Halloran Christopher M.,Mayerle Julia,Oláh Attila,Jackson Richard,Rawcliffe Charlotte L.,Scarpa Aldo,Bassi Claudio,Büchler Markus W.
Publisher
Oxford University Press (OUP)
Reference34 articles.
1. Understanding metastasis in pancreatic cancer: a call for new clinical approaches;Tuveson;Cell,2012
2. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines;Tempero;J Natl Compr Canc Netw,2012
3. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel;Van Laethem;Ann Oncol,2012
4. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011
5. Results of a randomized phase III trial (MPACT) of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates;Von Hoff;J Clin Oncol,2013